Eyeworld

APR 2019

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/1097941

Contents of this Issue

Navigation

Page 63 of 166

844.446.6979 *For professional use only. ImprimisRx specializes in customizing medications to meet unique patient and practitioner needs. No compounded medication is reviewed by the FDA for safety or e•icacy. ImprimisRx does not compound copies of commercially available products. References available upon request. ImprimisRx, Tri-Moxi, Dex-Moxi, Dex-Moxi-Ketor, and MKO Melt are trademarks of Harrow Health, Inc. ©2019 ImprimisRx. All rights reserved. IMPO0359 03/19 As of 03.04.19 For All Your Surgical Needs From our FDA-Registered Outsourcing Facility Order at: www.order.imprimisrx.com Injectable Formulations Other Formulations Tri-Moxi® (Triamcinolone acetonide and moxifloxacin hydrochloride) 15mg/1mg/mL Dex-Moxi® (Dexamethasone and moxifloxacin hydrochloride) 1mg/5mg/mL Dex-Moxi-Ketor® (Dexamethasone, moxifloxacin hydrochloride and ketorolac) 1mg/0.5mg/0.4mg/mL Moxifloxacin 5mg/mL and 1mg/mL Hyaluronidase 175 units/mL MKO Melt® Sublingual Lemon (Midazolam, ketamine HCL and ondansetron) (3/25/2) mg Providone Iodine 5% Lidocaine/ Epinephrine in BSS (PF/SF) (0.75/0.025)% Phenylephrine/Lidocaine (PF/SF) (1.5/1)% Topical Formulations Steroid, Antibiotic, NSAID Steroid, Antibiotic Steroid, NSAID Visit us at ASCRS Booth #1427

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld - APR 2019